CClinicalTrials.gg
Status unknownNCT05069233Updated Oct 6, 2021

Magnetically Controlled Capsule Endoscopy in Visualization of the UGI and Small Intestine

An observational study in Stomach Diseases and Small Intestine Disease, sponsored by Changhai Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-10-06.

Sponsored by Changhai Hospital · Observational

The sponsor has not verified this record recently (last verified Sep 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
593
Ages
18 Years and older
Sex
All
01

Study summary

In this study, we retrospectively analyzed the videos of combined upper digestive tract and small intestine examination under MCE, so as to clarify the feasibility and diagnostic efficacy of MCE in one-time examination of the upper gastrointestinal and small intestinal mucosa.

Read the detailed description

Magnetically controlled capsule endoscopy (MCE), with equally favorable diagnostic accuracy as conventional endoscopy, has become a painless noninvasive diagnostic modality in clinical practice. The more than 8 hours battery life of the MCE enables a further examination of the small bowel. In addition, it has been demonstrated that magnetic steering of capsule endoscopy improves the completion rate of small bowel examination by facilitating passage of the capsule through the pylorus, which further supported MCE as a practical modality for examination of both the stomach and small bowel. In this study, we retrospectively analyzed the videos of combined upper digestive tract and small intestine examination under MCE, so as to clarify the feasibility and diagnostic efficacy of MCE in one-time examination of the upper gastrointestinal and small intestinal mucosa.

02

Conditions studied

  • Stomach Diseases
  • Small Intestine Disease

Keywords

  • capsule endoscopy
03

In context

Stomach Diseases

50 studies on the registry are indexed under Stomach Diseases; 7 are open to participants now.

This study's planned enrollment of 593 is above the median of 397 across 12 observational studies indexed under Stomach Diseases.

Browse Stomach Diseases studies →

Lead sponsor

Changhai Hospital is the lead sponsor of 342 studies on the registry; 133 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Patients who underwent upper gastrointestinal and small intestinal mucosal examination under MCE at Shanghai Changhai Hospital and Chinese PLA General Hospital after January 2020.

Inclusion criteria

  1. Age ≥ 18 years old.
  2. Those who underwent upper gastrointestinal and small intestinal mucosal examination under magnetically controlled capsule endoscopy at Shanghai Changhai Hospital and Chinese PLA General Hospital after January 2020.
  3. Able to provide informed consent.

Exclusion criteria

Exclusion Criteria:

  1. Patients who fail to follow the prescribed procedures for magnetically controlled capsule endoscopy;
  2. Patients who only undergo gastric examination under magnetically controlled capsule endoscopy;
  3. Patients who only undergo small bowel examination under magnetic control capsule endoscopy;
  4. The patient's basic information in the database is incomplete;
  5. Patient fail to be followed up.
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
593 participants (estimated)
Patient registry
No

Groups and cohorts

  • UGI+SB

    Patients who underwent combined upper digestive tract and small intestine examination under MCE.

    Other: UGI+SB

Interventions

  • OtherUGI+SB

    Patients who underwent combined upper digestive tract and small intestine examination under MCE.

06

What researchers measure

Primary outcomes

  1. Success rate of UGI and small-bowel examination

    The success rate of upper gastrointestinal tract and small-bowel examination under MCE is evaluated by the technical success rate, a composite outcome including the successful viewing of esophagus, stomach and duodenum, and complete small-bowel examination.

    Time frame: 2 weeks

Secondary outcomes

  1. Visualization of the esophagus

    Visualization of the esophagus indicated by the number of images captured for Z-line and how many quadrants of the Z-line were observed. Circumferential visualization of the Z-line is defined by quadrants as follows: less than 2 quadrants (\< 50%) observed; at least 2 quadrants (50%-75%) observed; at least 3 quadrants (\>75%) observed; and entire structure (100%) observed.

    Time frame: 2 weeks

  2. Visualization score of the gastric mucosa

    Visualization score of the gastric mucosa To objectively evaluate the complete visualization of the gastric mucosa in the 6 anatomic landmarks (cardia, fundus, body, angulus, antrum, and pylorus), a 3-point grading scale was used: 1, poor (\<70% of the mucosa was observed), 2, fair (70%-90% of the mucosa was observed), and 3, good (\>90% of the mucosa was observed).

    Time frame: 2 weeks

  3. Visualization of the small bowel

    Visualization of the small bowel was determined by the percentage of time during which the small-bowel view was clear, defined as not obscured more than 50% of the screen view. The clear-viewing percentage of the total small-bowel transit time assessed by a 4-point scale :0, less than 25%; 1, 25% to 49%; 2, 50% to 75%; and 3, greater than 75%.

    Time frame: 2 weeks

  4. Examination time of esophagus, stomach, duodenum and small bowel

    Examination-related parameters included esophageal transit time (ETT), gastric examination time (GET), gastric transit time (GTT), pylorus transit time (PTT), small bowel transit time (SBTT). ETT is defined as the time between the first esophageal image and the first gastric image. GTT is defined as the time between the first gastric image and the first duodenal image. GET is defined as the time for examination of gastric primary anatomic landmarks twice. PTT is defined as the time between the first pyloric image and the first duodenal image. SBTT is defined as the time between the first duodenal image and the first cecal image.

    Time frame: 1 month

  5. Detection rate of lesions

    The detection rate of lesions in different digestive part (esophagus, stomach, duodenum, small intestine) found by MCE.

    Time frame: 1 month

  6. Adverse events during MCE procedure

    The presence of any adverse events during MCE procedure will be recorded.

    Time frame: 1 month

07

Study locations

1 of 1 sites recruiting
  • Changhai Hospital
    Shanghai, 200433, China
    • Zhuan Liao, professor · Contact · liaozhuan@smmu.edu.cn · 86-021-31161004
    • Xi Jiang · Sub investigator
    • Yawei Liu · Sub investigator
    Recruiting
08

References and documents

Publications

  • Liao Z, Hou X, Lin-Hu EQ, Sheng JQ, Ge ZZ, Jiang B, Hou XH, Liu JY, Li Z, Huang QY, Zhao XJ, Li N, Gao YJ, Zhang Y, Zhou JQ, Wang XY, Liu J, Xie XP, Yang CM, Liu HL, Sun XT, Zou WB, Li ZS. Accuracy of Magnetically Controlled Capsule Endoscopy, Compared With Conventional Gastroscopy, in Detection of Gastric Diseases. Clin Gastroenterol Hepatol. 2016 Sep;14(9):1266-1273.e1. doi: 10.1016/j.cgh.2016.05.013. Epub 2016 May 20. PubMed 27211503 ↗
  • Jiang X, Qian YY, Liu X, Pan J, Zou WB, Zhou W, Luo YY, Chen YZ, Li ZS, Liao Z. Impact of magnetic steering on gastric transit time of a capsule endoscopy (with video). Gastrointest Endosc. 2018 Oct;88(4):746-754. doi: 10.1016/j.gie.2018.06.031. Epub 2018 Jul 11. PubMed 30005825 ↗
  • Luo YY, Pan J, Chen YZ, Jiang X, Zou WB, Qian YY, Zhou W, Liu X, Li ZS, Liao Z. Magnetic Steering of Capsule Endoscopy Improves Small Bowel Capsule Endoscopy Completion Rate. Dig Dis Sci. 2019 Jul;64(7):1908-1915. doi: 10.1007/s10620-019-5479-z. Epub 2019 Feb 6. PubMed 30725289 ↗
  • Chen X, Gao F, Zhang J. Screening for Gastric and Small Intestinal Mucosal Injury with Magnetically Controlled Capsule Endoscopy in Asymptomatic Patients Taking Enteric-Coated Aspirin. Gastroenterol Res Pract. 2018 Nov 15;2018:2524698. doi: 10.1155/2018/2524698. eCollection 2018. PubMed 30581462 ↗
  • Liu YW, Wang YC, Zhu JH, Jiang X, Zhou W, Zhang J, Liao Z, Linghu EQ. Magnetically controlled capsule endoscopy in one-time gastro-small intestinal joint examination: a two-centre experience. BMC Gastroenterol. 2022 May 4;22(1):222. doi: 10.1186/s12876-022-02302-0. PubMed 35509022 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05069233
Lead sponsor
Changhai Hospital
Collaborators
Chinese PLA General Hospital
Responsible party
Zhuan Liao (Professor, Changhai Hospital) — Principal investigator
First posted
Oct 6, 2021
Start date
Sep 27, 2021
Primary completion
Dec 28, 2021 (estimated)
Completion
Dec 30, 2021 (estimated)
Last update
Oct 6, 2021

Study contacts

Zhuan Liao, Professor
Contact
zhuanleo@126.com
(81)02131161024
Xi Jiang, PhD
Contact
jiangxi_stella@126.com
81-13127952352
Zhuan Liao
principal investigator · Changhai Hospital,Shanghai,China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion